
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8196394/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer?. Chest, 2013, 143, e93S-e120S.	0.8	1,092
2	The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic. Chest, 2020, 158, 106-116.	0.8	832
3	The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology, 2020, 296, 172-180.	7.3	721
4	Detection of Lung Cancer by Sensor Array Analyses of Exhaled Breath. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1286-1291.	5.6	514
5	Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Annals of the American Thoracic Society, 2019, 16, 22-28.	3.2	458
6	Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 412-441.	4.9	432
7	Electromagnetic Navigation Diagnostic Bronchoscopy. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 982-989.	5.6	405
8	Screening for Lung Cancer. Chest, 2013, 143, e78S-e92S.	0.8	399
9	Incidence of Pneumonitis With Use of ProgrammedÂDeath 1 and Programmed Death-Ligand 1 InhibitorsÂinÂNon-Small CellÂLungÂCancer. Chest, 2017, 152, 271-281.	0.8	381
10	Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. Journal of Thoracic Oncology, 2019, 14, 343-357.	1.1	306
11	Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array. Thorax, 2007, 62, 565-568.	5.6	266
12	Screening for Lung Cancer. Chest, 2018, 153, 954-985.	0.8	266
13	American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation and Management for High-Risk Patients With Stage I Non-small Cell Lung Cancer. Chest, 2012, 142, 1620-1635.	0.8	223
14	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 651-665.	1.1	211
15	Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 137-142.	1.1	201
16	The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1433-1446.	1.1	201
17	An Official American Thoracic Society/American College of Chest Physicians Policy Statement: Implementation of Low-Dose Computed Tomography Lung Cancer Screening Programs in Clinical Practice. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 881-891.	5.6	199
18	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal of Thoracic Oncology, 2016, 11, 639-650.	1.1	182

#	Article	IF	CITATIONS
19	Components Necessary for High-Quality Lung Cancer Screening. Chest, 2015, 147, 295-303.	0.8	179
20	Analysis of Volatile Organic Compounds in the Exhaled Breath for the Diagnosis of Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 774-780.	1.1	170
21	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal of Thoracic Oncology, 2016, 11, 666-680.	1.1	170
22	Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. Clinics in Chest Medicine, 2002, 23, 137-158.	2.1	149
23	Comprehensive Analysis of Pulmonary Function Test (PFT) Changes After Stereotactic Body Radiotherapy (SBRT) for Stage I Lung Cancer in Medically Inoperable Patients. Journal of Thoracic Oncology, 2009, 4, 838-844.	1.1	149
24	Lung cancer biomarkers in exhaled breath. Expert Review of Molecular Diagnostics, 2011, 11, 207-217.	3.1	147
25	Pathophysiological Impact of Cigarette Smoke Exposure on the Cerebrovascular System with a Focus on the Blood-brain Barrier: Expanding the Awareness of Smoking Toxicity in an Underappreciated Area. International Journal of Environmental Research and Public Health, 2010, 7, 4111-4126.	2.6	139
26	A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic Experience. Journal of Thoracic Oncology, 2009, 4, 976-982.	1.1	126
27	Evaluating the Patient With a Pulmonary Nodule. JAMA - Journal of the American Medical Association, 2022, 327, 264.	7.4	122
28	Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules. Chest, 2018, 154, 491-500.	0.8	114
29	Screening for Lung Cancer. Chest, 2021, 160, e427-e494.	0.8	114
30	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 681-692.	1.1	101
31	Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. American Journal of Respiratory and Critical Care Medicine, 2017, 196, e15-e29.	5.6	95
32	Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic. Chest, 2020, 158, 406-415.	0.8	95
33	The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer, 2012, 12, 410.	2.6	93
34	Impact of a Lung Cancer Screening Counseling and Shared Decision-Making Visit. Chest, 2017, 151, 572-578.	0.8	89
35	Frequency of Incidental Findings and Subsequent Evaluation in Low-Dose Computed Tomographic Scans for Lung Cancer Screening. Annals of the American Thoracic Society, 2017, 14, 1450-1456.	3.2	82
36	Impact of Induction Concurrent Chemoradiotherapy on Pulmonary Function and Postoperative Acute Respiratory Complications in Esophageal Cancer. Chest, 2005, 128, 250-255.	0.8	67

#	Article	IF	CITATIONS
37	Serum Free Fatty Acid Biomarkers of Lung Cancer. Chest, 2014, 146, 670-679.	0.8	64
38	Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e3-e13.	5.6	63
39	The Utility of Exercise Testing in Patients with Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1397-1410.	1.1	62
40	S100Î <sup>2</sup> as a predictor of brain metastases. Cancer, 2005, 104, 817-824.	4.1	59
41	Bronchogenic Carcinoma after Lung Transplantation: Characteristics and Outcomes. Journal of Thoracic Oncology, 2008, 3, 1404-1409.	1.1	59
42	Validation of a Multiprotein Plasma Classifier to Identify Benign Lung Nodules. Journal of Thoracic Oncology, 2015, 10, 629-637.	1.1	55
43	Interpreting pulmonary function tests: recognize the pattern, and the diagnosis will follow Cleveland Clinic Journal of Medicine, 2003, 70, 866-866.	1.3	52
44	Exhaled breath volatile organic compound biomarkers in lung cancer. Journal of Breath Research, 2012, 6, 027106.	3.0	52
45	NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 754-764.	4.9	52
46	Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer. Chest, 2017, 151, 861-874.	0.8	50
47	Models to Estimate the Probability of Malignancy in Patients with Pulmonary Nodules. Annals of the American Thoracic Society, 2018, 15, 1117-1126.	3.2	48
48	Biomarkers in Lung Cancer. Clinics in Chest Medicine, 2020, 41, 115-127.	2.1	46
49	Preoperative evaluation of the lung resection candidate. Cleveland Clinic Journal of Medicine, 2012, 79, S17-S22.	1.3	43
50	Discordant utility of ideal body weight and body mass index as predictors of mortality in lung transplant recipients. Journal of Heart and Lung Transplantation, 2005, 24, 137-144.	0.6	42
51	Lung cancer: Preoperative pulmonary evaluation of the lung resection candidate. American Journal of Medicine, 2005, 118, 578-583.	1.5	42
52	Metabolite Profiles of the Serum of Patients with Non–Small Cell Carcinoma. Journal of Thoracic Oncology, 2016, 11, 72-78.	1.1	41
53	Evaluation of a Serum Lung Cancer Biomarker Panel. Biomarker Insights, 2018, 13, 117727191775160.	2.5	41
54	Cell-mediated immune response to influenza vaccination in lung transplant recipients. Journal of Heart and Lung Transplantation, 2004, 23, 1175-1181.	0.6	39

#	Article	IF	CITATIONS
55	In Vitro Assessment of Tobacco Smoke Toxicity at the BBB: Do Antioxidant Supplements Have a Protective Role?. BMC Neuroscience, 2011, 12, 92.	1.9	38
56	ProApolipoprotein A1. Cancer, 2008, 112, 1313-1324.	4.1	35
57	Electromagnetic Navigational Bronchoscopy versus CT-guided Percutaneous Sampling of Peripheral Indeterminate Pulmonary Nodules: A Cohort Study. Radiology, 2018, 286, 1052-1061.	7.3	35
58	Stakeholder Research Priorities for Smoking Cessation Interventions within Lung Cancer Screening Programs. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1202-1212.	5.6	30
59	Endocrine paraneoplastic syndromes in lung cancer. Current Opinion in Pulmonary Medicine, 2003, 9, 313-320.	2.6	29
60	Definition and assessment of high risk in patients considered for lobectomy for stage I non–small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 1605-1618.e6.	0.8	29
61	Bias, underestimation of risk, and loss of statistical power in patient-level analyses of lesion detection. European Radiology, 2010, 20, 584-594.	4.5	28
62	Quality Indicators for the Evaluation of Patients With Lung Cancer. Chest, 2014, 146, 659-669.	0.8	28
63	Phenotypes and Subphenotypes of Patients With COVID-19. Chest, 2021, 159, 2191-2204.	0.8	28
64	Progress in the Development of Volatile Exhaled Breath Signatures of Lung Cancer. Annals of the American Thoracic Society, 2015, 12, 752-757.	3.2	27
65	Proposed Quality Metrics for Lung Cancer Screening Programs. Chest, 2021, 160, 368-378.	0.8	27
66	Development of a Risk Prediction Model to Estimate the Probability of Malignancy in Pulmonary Nodules Being Considered for Biopsy. Chest, 2019, 156, 367-375.	0.8	26
67	Exercise capacity and cancer-specific quality of life following curative intent treatment of stage l–IIIA lung cancer. Supportive Care in Cancer, 2018, 26, 2459-2469.	2.2	25
68	Association of impaired heart rate recovery with cardiopulmonary complications after lung cancer resection surgery. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 1168-1173.e3.	0.8	24
69	S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer. Translational Lung Cancer Research, 2016, 5, 413-419.	2.8	23
70	Multicenter Study of Temporal Changes and Prognostic Value of a CT Visual Severity Score in Hospitalized Patients With Coronavirus Disease (COVID-19). American Journal of Roentgenology, 2021, 217, 83-92.	2.2	23
71	Pulmonary Alveolar Proteinosis: Recent Advances. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 115-126.	2.1	22
72	Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer. BMC Cancer, 2015, 15, 1001.	2.6	22

#	Article	IF	CITATIONS
73	Preoperative evaluation of the patient with lung cancer being considered for lung resection. Current Opinion in Anaesthesiology, 2015, 28, 18-25.	2.0	22
74	Routine venous thromboembolism screening after pneumonectomy: The more you look, the more you see. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 524-532.e2.	0.8	22
75	Survival in Patients with Metachronous Second Primary Lung Cancer. Annals of the American Thoracic Society, 2015, 12, 79-84.	3.2	20
76	RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs. BMC Pulmonary Medicine, 2018, 18, 42.	2.0	20
77	Identifying delays in care for patients with NSCLC using value-stream mapping Journal of Clinical Oncology, 2018, 36, 136-136.	1.6	20
78	Lung Cancer: Preoperative Pulmonary Evaluation of the Lung Resection Candidate. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 271-284.	2.1	18
79	Randomized phase II trial of sulindac for lung cancer chemoprevention. Lung Cancer, 2013, 79, 254-261.	2.0	18
80	Quality of Life and Healthcare Use in a Randomized Controlled Lung Cancer Screening Study. Annals of the American Thoracic Society, 2013, 10, 324-329.	3.2	18
81	Histologic and Molecular Characterization of Lung Cancer With Tissue Obtained by Electromagnetic Navigation Bronchoscopy. Journal of Bronchology and Interventional Pulmonology, 2013, 20, 10-15.	1.4	18
82	Lung Cancer Screening with Computer Aided Detection Chest Radiography: Design and Results of a Randomized, Controlled Trial. PLoS ONE, 2013, 8, e59650.	2.5	18
83	Paraneoplastic syndromes associated with bronchogenic carcinoma. Clinics in Chest Medicine, 2002, 23, 257-264.	2.1	17
84	Small Vessel Ischemic Disease of the Brain and Brain Metastases in Lung Cancer Patients. PLoS ONE, 2009, 4, e7242.	2.5	17
85	Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic. Journal of the American College of Radiology, 2020, 17, 845-854.	1.8	17
86	Critical care journals during the COVID-19 pandemic: challenges and responsibilities. Intensive Care Medicine, 2020, 46, 1521-1523.	8.2	17
87	Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. Radiology Imaging Cancer, 2020, 2, e204013.	1.6	17
88	Lung cancer screening. Current Oncology Reports, 2007, 9, 265-274.	4.0	16
89	The Integral Role of the Electronic Health Record and Tracking Software in the Implementation of Lung Cancer Screening—A Call to Action to Developers. Chest, 2020, 157, 1674-1679.	0.8	16
90	Progress in the development of a diagnostic test for lung cancer through the analysis of breath volatiles. Journal of Breath Research, 2008, 2, 037014.	3.0	15

6

#	Article	IF	CITATIONS
91	Sniffing out lung cancer. Nature Nanotechnology, 2009, 4, 621-622.	31.5	15
92	A Comparison of Four Versions of a Computer-aided Detection System for Pulmonary Nodules on Chest Radiographs. Journal of Thoracic Imaging, 2012, 27, 58-64.	1.5	15
93	Sampling Utility of the Convex Probe Endobronchial Ultrasound Visible Intrapulmonary Lesion. Journal of Bronchology and Interventional Pulmonology, 2018, 25, 290-299.	1.4	15
94	Impact of the Percepta Genomic Classifier on Clinical Management Decisions in a Multicenter Prospective Study. Chest, 2021, 159, 401-412.	0.8	15
95	The rationale for, and design of, a lung cancer screening program. Cleveland Clinic Journal of Medicine, 2012, 79, 337-345.	1.3	15
96	What's the Control in Studies Measuring the Effect of Computer-Aided Detection (CAD) on Observer Performance?. Academic Radiology, 2010, 17, 761-767.	2.5	14
97	A Comparison of Follow-Up Recommendations by Chest Radiologists, General Radiologists, and Pulmonologists Using Computer-Aided Detection to Assess Radiographs for Actionable Pulmonary Nodules. American Journal of Roentgenology, 2011, 196, W542-W549.	2.2	14
98	Lung Cancer Screening: Characteristics of Nonparticipants and Potential Screening Barriers. Clinical Lung Cancer, 2020, 21, e329-e336.	2.6	14
99	An integrated risk predictor for pulmonary nodules. PLoS ONE, 2017, 12, e0177635.	2.5	14
100	The pulmonologist's perspective regarding the solitary pulmonary nodule. Seminars in Thoracic and Cardiovascular Surgery, 2002, 14, 250-260.	0.6	13
101	Radon and lung cancer: Assessing and mitigating the risk. Cleveland Clinic Journal of Medicine, 2014, 81, 567-575.	1.3	13
102	New Onset Left Bundle Branch Block With Right Axis Deviation in a Patient With Wegener's Granulomatosis. Journal of Electrocardiology, 2000, 33, 199-201.	0.9	12
103	The combined rapid detection and species-level identification of yeasts in simulated blood culture using a colorimetric sensor array. PLoS ONE, 2017, 12, e0173130.	2.5	12
104	Lung cancer screening: is it time for a change in policy?. Cleveland Clinic Journal of Medicine, 2007, 74, 441-448.	1.3	12
105	Cystic lung disease: Systematic, stepwise diagnosis. Cleveland Clinic Journal of Medicine, 2015, 82, 115-127.	1.3	12
106	Extrapleural pneumonectomy for scimitar syndrome. Journal of Thoracic and Cardiovascular Surgery, 2006, 132, 704-705.	0.8	10
107	Heart Rate Recovery as a Preoperative Test of Perioperative Complication Risk. Annals of Thoracic Surgery, 2015, 100, 1954-1962.	1.3	10
108	A rational approach to the evaluation and treatment of the infected patient in the intensive care unit. Clinics in Chest Medicine, 2003, 24, 645-669.	2.1	9

#	Article	IF	CITATIONS
109	Cause and Effect in Lung Cancer. Chest, 2005, 128, 6-8.	0.8	9
110	Lung Cancer Screening: An Update, Discussion, and Look Ahead. Current Oncology Reports, 2010, 12, 226-234.	4.0	9
111	Is Lung Cancer in the Nonsmoker a Different Disease?. Chest, 2004, 126, 326-329.	0.8	8
112	Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists. Respiratory Medicine, 2012, 106, 473-492.	2.9	8
113	Assessment of Integrated Classifier's Ability to Distinguish Benign From Malignant Lung Nodules. Chest, 2021, 159, 1283-1287.	0.8	8
114	Muscle pain after exercise. Lancet, The, 1999, 353, 1062.	13.7	7
115	Obstacles to and Solutions for a Successful Lung Cancer Screening Program. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 659-669.	2.1	7
116	Can the Electronic Nose Really Sniff out Lung Cancer?. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1060-1061.	5.6	7
117	Detection of brain-directed autoantibodies in the serum of non-small cell lung cancer patients. PLoS ONE, 2017, 12, e0181409.	2.5	6
118	Association of Exercise Behavior with Overall Survival in Stage l–IIIA Lung Cancer. Annals of the American Thoracic Society, 2021, 18, 1034-1042.	3.2	6
119	How Many Ways Can We Say That Cigarette Smoking Is Bad for You?. Chest, 2004, 126, 1717-1718.	0.8	5
120	COUNTERPOINT: Should Lung Cancer Screening Be Expanded to Persons Who Don't Currently Meet Accepted Criteria Set Forth by the CHEST Guidelines on Lung Cancer Screening? No. Chest, 2018, 153, 1303-1305.	0.8	5
121	Clinical validation and utility of Percepta GSC for the evaluation of lung cancer. PLoS ONE, 2022, 17, e0268567.	2.5	5
122	Rapid on-site evaluation of endobronchial ultrasound–guided fine-needle aspirates: correlation of adequacy assessment and final diagnosis in patients with bronchogenic carcinoma. Journal of the American Society of Cytopathology, 2014, 3, 199-205.	0.5	4
123	Endobronchial pleomorphic adenoma. Oxford Medical Case Reports, 2016, 2016, omw090.	0.4	4
124	Lung cancer screening: Examining the issues. Cleveland Clinic Journal of Medicine, 2012, 79, S1-S6.	1.3	4
125	Heart rate recovery and survival in patients undergoing stereotactic body radiotherapy for treatment of early-stage lung cancer. Journal of Radiosurgery and SBRT, 2015, 3, 193-201.	0.2	4
126	Acute Dyspnea and Hypoxia in a 37-Year-Old Woman With Sarcoidosis. Chest, 1998, 113, 830-833.	0.8	3

#	Article	IF	CITATIONS
127	Beyond the Usual Suspects. Journal of Thoracic Oncology, 2012, 7, 1477-1478.	1.1	3
128	The Analysis of Volatile Organic Compound Profiles in the Breath as a Biomarker of Lung Cancer. Chest, 2013, 144, 645A.	0.8	3
129	The CHEST Team. Chest, 2020, 158, 1-2.	0.8	3
130	Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials Journal of Clinical Oncology, 2017, 35, e20647-e20647.	1.6	3
131	Lung Cancer Screening. Surgical Oncology Clinics of North America, 2020, 29, 509-524.	1.5	3
132	Systemic Vasculitis and Polyarthritis as the Presenting Feature of Renal Cell Carcinoma. Journal of Clinical Rheumatology, 1998, 4, 266-269.	0.9	2
133	Give me a sign, any sign. Thorax, 2009, 64, 737-738.	5.6	2
134	An Attempt to Reach the Galaxy of the Pulmonary Nodules. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 264-265.	5.6	2
135	Rebuttal From Dr Mazzone. Chest, 2018, 153, 1306-1308.	0.8	2
136	Creating and Scaling a High-Quality Lung Cancer Screening Program. NEJM Catalyst, 2020, 1, .	0.7	2
137	Q: Does noninvasive positive pressure ventilation have a role in managing hypercapnic respiratory failure due to an acute exacerbation of COPD?. Cleveland Clinic Journal of Medicine, 2008, 75, 458-461.	1.3	2
138	S100B as a Serum Marker for Early Detection of Brain Metastasis in Lung Cancer. Chest, 2013, 144, 644A.	0.8	1
139	The Utility of Rapid On-Site Evaluation (ROSE) in the Detection of Granulomas in Mediastinal Lymph Nodes. Chest, 2013, 144, 797A.	0.8	1
140	The Analysis of Small Molecule Metabolite Profiles in the Blood as a Biomarker of Lung Cancer. Chest, 2014, 146, 587A.	0.8	1
141	Pulmonary Lung Cancer Subspecialty Training. Journal of Bronchology and Interventional Pulmonology, 2015, 22, 281-285.	1.4	1
142	The Frequency of Incidental Findings and Subsequent Testing in Low-Dose CT Scans for Lung Cancer Screening. Chest, 2016, 150, 658A.	0.8	1
143	Healthy Patients at Risk for Lung Cancer. , 2018, , 197-208.		1
144	Principled Lung Cancer Screening Follows Screening Principles. Chest, 2018, 154, 1265-1266.	0.8	1

#	Article	IF	CITATIONS
145	Response. Chest, 2018, 154, 997-998.	0.8	1
146	A Year of Progress and Learning. Chest, 2021, 160, 1-2.	0.8	1
147	Hypotension in the intensive care unit Cleveland Clinic Journal of Medicine, 2006, 73, 1091-1097.	1.3	1
148	Preoperative Pulmonary Evaluation. , 2012, , 869-875.		0
149	The Utility of EBUS-TBNA in Diagnosing Hodgkin's Lymphoma. Chest, 2013, 144, 795A.	0.8	0
150	The Accuracy of Quantitative CT Scan Based Prediction of Post-Lung Resection FEV 1. Chest, 2015, 148, 555A.	0.8	0
151	Call the Pulmonologist? The Role of Pulmonary Specialists in the Care of Lung Cancer Patients with Chronic Obstructive Pulmonary Disease in a Time of Cost Constraints. Annals of the American Thoracic Society, 2015, 12, 627-628.	3.2	0
152	Endobronchial ultrasonography-guided transbronchial needle aspiration, an effective modality for sampling targeted thoracic lesions in adult lung transplant recipients. Journal of the American Society of Cytopathology, 2015, 4, 321-326.	0.5	0
153	Evaluation of pulmonary nodules: an update. Minerva Respiratory Medicine, 2017, 56, .	0.2	0
154	CLINICAL UTILITY OF A BRONCHIAL GENOMIC CLASSIFIER FOR LUNG CANCER DETECTION: RESULTS FROM A MULTICENTER PROSPECTIVE REGISTRY. Chest, 2018, 154, 597A-599A.	0.8	0
155	Response. Chest, 2018, 154, 716-717.	0.8	0
156	Models to Estimate the Probability of Malignancy in Patients with Pulmonary Nodules. Annals of the American Thoracic Society, 2018, , .	3.2	0
157	The CHEST Editorial Team. Chest, 2019, 156, 1-3.	0.8	0
158	Molecular biomarkers for the evaluation of lung nodules. Lancet Respiratory Medicine,the, 2019, 7, 297-298.	10.7	0
159	IMPROVING INDETERMINANT PULMONARY NODULE MANAGEMENT WITH THE PERCEPTA GENOMIC SEQUENCING CLASSIFIER. Chest, 2019, 156, A2271-A2272.	0.8	0
160	Introduction. Chest, 2020, 158, S1-S2.	0.8	0
161	SURVIVAL IN COPD PATIENTS WITH STAGE 1 NON-SMALL CELL LUNG CANCER. Chest, 2020, 158, A1463.	0.8	0
162	Multiple Pulmonary Nodules in an Elderly Woman. Journal of Thoracic Oncology, 2006, 1, 580-581.	1.1	0

#	Article	IF	CITATIONS
163	CAN THE MODERN PRESENTATION OF LUNG CANCER GUIDE THE SELECTION OF POPULATIONS TO SCREEN?. Chest, 2006, 130, 115S.	0.8	Ο
164	A small pulmonary nodule, found incidentally Cleveland Clinic Journal of Medicine, 2007, 74, 531-533.	1.3	0
165	Pulmonary nodule on x-ray: An algorithmic approach. Journal of Family Practice, 2016, 65, 103-11.	0.2	0